Foreign Direct Investment, Technological Capabilities and Performance in the Chinese Pharmaceutical Industry
Does a firm engage in a joint venture with a technologically advanced foreign partner to complement or substitute investments in its own technological capabilities? We address this question in a comparative study of 222 Chinese pharmaceutical manufacturers and Sino-foreign joint ventures. A combination of ANOVA and OLS regression results provide evidence that firms with joint ventures invest more in organizational resources associated with technological capabilities, are higher performing by a number of absolute and relative measures, and have different correlates of high performance than firms without joint ventures. While the study cannot address the question of direction of causality, it does provide support for the view that joint ventures and investments in organizational resources are complementary, or at least correlated, rather than substitution strategies.
To our knowledge, this item is not available for
download. To find whether it is available, there are three
1. Check below under "Related research" whether another version of this item is available online.
2. Check on the provider's web page whether it is in fact available.
3. Perform a search for a similarly titled item that would be available.
|Date of creation:||Oct 1997|
|Date of revision:|
|Contact details of provider:|| Postal: |
Phone: +81-(0)78 803 7036
Fax: +81-(0)78 803 7059
Web page: http://www.rieb.kobe-u.ac.jp/index-e.html
More information through EDIRC
When requesting a correction, please mention this item's handle: RePEc:kob:dpaper:86. See general information about how to correct material in RePEc.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: (Office of Promoting Research Collaboration, Research Institute for Economics & Business Administration, Kobe University)
If references are entirely missing, you can add them using this form.